Clinical Trial Update: Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ipilimumab and nivolumab with immunoembolization for metastatic uveal melanoma to the liver has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2023-11-29